Figure S2 | Vectra analysis of residual disease samples.

A) Total immune infiltration per mm2 within pre-treatment (baseline) and residual disease samples (RCB II/III) among i) ER+HER2- and ii) TNBC tumours.

B) Stacked bar graph showing the tumoural and stromal PD-L1 expression in TNBC and ER+HER2- RCB II/III disease.

C) C i-ii) Percentage of tumoral and stromal PD-L1 expression within the TME of ER+HER2- RCB II/III disease.

C iii-iv) Percentage of PD-1 expression on immune cells within the invasive tumour (iii) and tumour stroma (iv) in ER+HER2- RCB II/III disease (Mann Whitney test).